To evaluate the difference between combination pharmacotherapy and monotherapy on low back pain (LBP).
We searched PubMed, Embase, and Cochrane Central Register of Controlled Trials databases up to March 14, 2017. Two authors independently extracted the data and assessed the validity of included trials.
Twelve randomized controlled trials comparing the effect of LBP combination pharmacotherapy to monotherapy or placebo were included. In chronic LBP, combination pharmacotherapy was more effective than placebo in pain relief (P<0.001; standardized mean difference [SMD], −0.50; 95% confidence interval [CI], −0.70 to −0.29; I²=0%) and function improvement (P<0.001; SMD, −0.27; 95% CI, −0.41 to −0.13; I²=0%) and showed improved pain relief compared with monotherapy (P<0.001; SMD, −0.84; 95% CI, −1.12 to −0.56; I²=0%). Combination pharmacotherapy did not outperform monotherapy pain relief and function improvement in acute LBP. In addition, risk of adverse effects of combination pharmacotherapy was much higher compared with placebo (P<0.05; relative risk, 1.80; 95% CI, 1.33-2.42; I²>50%) and monotherapy (P<0.05; relative risk, 1.44; 95% CI, 1.01-2.06; I²>50%) in both settings.
Combination pharmacotherapy is more effective than placebo or monotherapy in the management of pain and disability in chronic LBP, but not in acute LBP. Further, combination pharmacotherapy has a higher risk of adverse effects than placebo and monotherapy.
*Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou
†College of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China
L.S., P.Q., and J.X. contributed equally.
This work was supported in part by the National Nature Science Fund of China, Hangzhou, Zhejiang Province (81702143 and 81772387). The authors declare no conflict of interest.
Reprints: Xianfeng Lin, MD and Xiangqian Fang, MD, 3 East Qingchun Road, Hangzhou, Zhejiang 310000, China (e-mails: email@example.com; firstname.lastname@example.org).
Received December 8, 2017
Received in revised form March 24, 2018
Accepted April 14, 2018